T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy ...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic ...

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Researchers at the Medical University of Vienna have uncovered how a little-studied protein, TRAT1 (T Cell Receptor ...

MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...